Kamil Idris Poses Threat of WWIII in JASTA

In a recent book by Kamil Idsris, the former director of WIPO and president of ICAM, says there is an underlying threat in the recently passed bill by Congress called JASTA. The Justice Against Sponsors of Terrorism Act was passed in 2016. JASTA is a bill passed by Congress that would ensure that terrorist, wherever they crop their heads up in defiance of the civil laws of the United States would never have the chance to repeat what happened on 9/11; in other words, any citizen, coming to a true like to terrorism, could in effect sue that country.

However, Professor Idris makes an argument in his latest book “JASTA” and a third world war, that one of the core principles in which international law is predicated is that a country is immune from lawsuits within the courts of another country. Professor Idris poses an intelligent question to the problem set forth in JASTA. If a country is foreign to lawsuits in another countries courts how can the lawsuit of an individual stand against another country in the same country’s court. Professor Idris calls to the attention of his readers the possibility of a realignment of countries that may lead to the United States being the target of the very terrorist attacks it seeks to avoid. Professor Idris has worked with numerous world leaders to avoid international crisis like Fidel Castro, Yasser Arafat, Bill Clinton and others. He argues in his book that there is a growing sense of worry and concern about JASTA and how especially its effect upon the erosion of “sovereign immunity,” while other international leaders say it is an indication that international law is under violation. Lastly, Professor Kamil Idris questions whether the passing of JASTA may also bring US under attack in his recent book, calling to mind that a countries “pressure to protect from independent legal legal claims,” which brings its “sovereignty” under attack, could lead to unpredictable outcomes by other nations towards the US.

Professor Kamil Idris now lives with his family in Durham, England.

Read Kamil Idris’s own words on the topic:

http://www.ie-forum.nl/artikelen/a-message-from-director-general-kamil-idris

 

What Scott Rocklage Built at 5AM Ventures

Scott Rocklage, the managing partner of 5 AM Ventures, has been a partner since 2004. When he joined the company in 2003, Rocklage was successful, rising to the top as a partner in just under one year. His expertise in the healthcare management marketplace gave him vast knowledge and experience in his field, enabling him to become a well qualified leader that would soon lead to getting FDA approvals for major drug applications. These applications included Omniscan, Teslascan, Cubicin and read full article.

Omniscan and Teslascan were both developed as an intravenous medication, while Cubicin was developed to treat bacterial infections of the skin and tissues. These drugs were noted as key solutions for those in need of medications for staph infections as well as for bringing images to fruition via MRI for brain injuries and other traumatic brain activity or events. Teslascan is specifically used for the purpose of creating image of the liver, in the case that detection is needed or vital for the detection of metastatic disease of the liver and learn more about Scott.

With more than 30 years of experience, Scott Rocklage has held many leadership positions during the course of his careers. Having worked with Cubist Pharmaceuticals later in his career, Rocklage was able to gain valuable experience that made him an effective strategist as a venture capitalist in healthcare. This unique position within the marketplace for healthcare gave Rocklage the experience he needed to become one of the most insightful investors in healthcare management as a whole.

He earned a Bachelor of Science Degree when studying at the University of California, and later earned a Nobel Prize in chemistry in 2005 and Scott’s lacrosse camp.

Eric Lefkofsky and the Tempus Touch

Eric Lefkofsky is an American entrepreneur who co-founded Groupon, among other ventures. Perhaps his most enduring contribution to the world is his efforts as co-founder and CEO of Tempus, a big data start-up dedicated to using cutting edge technology to fight cancer.

If that seems like a tall order, it is. But, that is nothing new to the serial entrepreneur who took a relatively obscure e-commerce site and turned it into one of the world’s largest e-commerce platforms. The idea is simple. Compile a massive genomic database that doctors can use to cross-reference and develop individualized cancer therapies. Hospitals, he discovered, weren’t able to take full advantage of technology designing initiatives to fight cancer. As a result, their ability to sequence patients and compare the data was limited. It needed to be scaled up.

So, Eric Lefkofsky did what he has always done when he sees a gap in the market. He found a way to fill it. While Tempus isn’t the first company of it’s kind, it is unique in that it presents an end-to-end solution to the problem of genomic mapping and cancer. Doctors and researchers are provided with testing facilities, access to databases, and a quick and easy way to cross-reference the information.

Lefkofsky stepped down from his post as CEO of Groupon in order to devote his time to Tempus. The extent of Lefkofsky’s involvement in the day to day operations of the company is unclear, as is the exact amount of his initial investment. It has been reported that he was prepared to invest up to $100 million. He is currently listed as the company’s CEO. Like all of Lefkofsky’s ventures, Tempus rely’s heavily on the big data component, channeling it into a force for good.

In an interview with Chicago business, Lefkofsky said that after establishing five successful companies, choosing to start Tempus was “very personal”. Perhaps this move isn’t a surprise to those who are familiar with the Lefkofsky Family Foundation, a charitable trust he and his wife established in 2006. It’s stated mission, “to advance high-impact programs, initiatives and research that enhance the quality of human life”, has helped to fund more than 50 organizations to date. It focuses on using technology, education, and science to improve the lives of people in the communities it serves.

Will Tempus revolutionize the way we treat cancer? That is hard to tell, but if anybody knows how to make big data work for humanity, it’s Eric Lefkofsky and contact his.

Stephen Murray, Economist and CEO of CCMP Capital

CCMP Capital was founded in 1984 and is a private equity company that specializes in leveraged buyout and also deals with growth capital transactions. CCMP focuses their attention in consumer and retail and service the telecom, media, energy, industrial, financial services and healthcare infrastructure sectors. The company offers expertise on content and programming, consumer and trade publishing, cable, broadcasting and wireless communications. With their involvement in the industrial world, they invest in the manufacturing, distribution and automotive sectors. CCMP also invests in the energy industry, focusing much of their attention on power generation, exploration, production and renewable energy departments.

Stephen Murray CCMP Capital has more than 50 experienced employees and operates from its main headquarters in New York City, New York, with additional headquarters in Tokyo and Hong Kong. Since its inception into the business world, CCMP Capital has dealt with approximately $12 billion in revenue pertaining to leveraged buyout and capital transactions, and CCMP was recognized to be among the top 20 World’s biggest private equity funds in 2007. In 2014, CCMP Capital sold Medpace, a pharmaceutical research organization, to Cinven for close to $900 million.

Originally named Chemical Venture Partners, starting in 1984, CCMP has had several names since then. Chemical Venture Partners acquired Chase Manhattan Bank in 1996, and subsequently changed its name to Chase Capital Partners. The company then changed its name to JP Morgan Partners after buying out J.P Morgan and Company in 2000. On July 31, 2006, JP Morgan Partners separated from JPMorgan Chase and came up with the CCMP name due to its prior company’s names (Chemical and Chase and JPMorgan Partners).

Stephen Murray, is the former CEO and president and also founded CCMP Capital. Stephen Murray CCMP Capital, a philanthropist and private equity investor, had an extensive background working on the board of several companies, including Generac Power Systems, AMC Entertainment, Aramark, Cabela’s, Pinnacle Foods, The Vitamin Shoppe, Warner Chilcott and Legacy Hospital Partners. Stephen P. Murray was born on August 2, 1962, in Brooklyn, New York. Stephen spent his childhood in North Tarrytown, New York, and went to Sleepy Hollow High School. He graduated with honors, obtaining a degree in Economics from Boston College in 1984. He earned his Master’s Degree in Business Administration in 1989, from Columbia Business School. After marrying his college sweetheart Tami Anne Monti, in 1985, he spent his 29 year marriage raising their children in Stamford, Connecticut. Stephen was an extraordinary asset to CCMP Capital and also a wonderful contributor to charities, such as the Food Bank of Lower Fairfield and the Make a Wish Foundation. Stephen Murray passed on March 12, 2015 according to the Wall Street Journal, and will always be remembered as a genius in Business, as well as a great family man.